Tesamorelin Overdose: A Product-and-Exposure Triage Record
At a glance
- Validated toxic dose / not identified
- Current EGRIFTA WR label overdosage section / none
- Product-specific antidote in the label / none described
- First useful distinction / WR, SV, older EGRIFTA, or an unverified product
- U.S. Poison Control / 1-800-222-1222
- Emergency symptoms / collapse, seizure, trouble breathing, or inability to awaken require 911
- Trial adverse events / context, not an overdose forecast
- Medical review / current review of this revision is pending
The Direct Authority Answer Is Triage, Not a “Safe Excess”
The National Library of Medicine's tesamorelin monograph states:
“In case of overdose, call the poison control helpline at 1-800-222-1222.”
MedlinePlus is a U.S. government health-information service. Its instruction routes an exposure to real-time toxicology assessment; it does not define a toxic dose, predict a benign course, or endorse tesamorelin or HealthRX.com (MedlinePlus, “In case of emergency/overdose”).
The same monograph directs 911 for collapse, seizure, breathing difficulty, or inability to awaken. Those are emergency triage criteria, not claimed tesamorelin-specific symptoms.
The Exposure Record That Changes the Answer
| Field | Why it matters | What not to infer |
|---|---|---|
| Exact product name | EGRIFTA WR and EGRIFTA SV have different strengths, preparation, and administration instructions | A vial labeled only “tesamorelin” is equivalent to either approved product |
| Concentration and formulation | A syringe volume is not an amount without a verified concentration | Volume alone establishes exposure |
| Intended and possible amount | A single repeated injection differs from a multi-day preparation error | The largest imaginable amount was actually delivered |
| Time and route | Triage depends on when and how exposure occurred | A plasma half-life sets the observation window |
| Current symptoms and vital signs | Immediate clinical state outranks a web dose table | No symptoms now guarantees no later problem |
| Other medicines and substances | Coexposures can change the risk and the differential | Every symptom belongs to tesamorelin |
| Product source and lot | An approved pharmacy-dispensed product has a traceable identity | An online product shares the approved product's purity or amount |
This record is useful because Poison Control or an emergency clinician can update the plan as product details and symptoms become clearer. It is not a home-monitoring protocol.
What the Current Label Does—and Does Not—Supply
The March 2025 EGRIFTA WR prescribing information includes dosing, warnings, adverse reactions, drug interactions, and specific-population sections, but no section 10 overdosage instructions. The label does warn about hypersensitivity, glucose intolerance, elevated IGF-1, fluid retention, and injection-site reactions in ordinary labeled exposure (EGRIFTA WR prescribing information).
Those labeled hazards are clinically relevant questions after an error. Their therapeutic-dose incidence cannot be converted into an overdose probability, and the absence of a label section cannot be converted into proof of safety.
The pivotal evidence pooled 740 treated adults with HIV and abdominal lipodystrophy under controlled protocols; it was not an escalating-dose toxicology study (PMID 20554713; DOI 10.1210/jc.2010-0490).
Why the Formulation Error Matters
EGRIFTA WR uses an 11.6 mg multi-dose vial and a labeled 1.28 mg daily dose. EGRIFTA SV uses 2 mg single-dose vials and different preparation instructions. FDA-approved labeling says the formulations are not substitutable. A numeric comparison detached from the label, vial, and concentration can therefore magnify an error rather than clarify it.
The older-adult dosing evidence audit keeps formulation and population claims separate. The food and supplement interaction map organizes possible coexposures, while the levothyroxine interaction review shows why mechanism alone cannot establish a dose adjustment.
What the Legacy Page Overstated
The previous article said tesamorelin overdose was not associated with life-threatening toxicity, assigned a “ceiling effect,” used a short half-life to limit severity, forecast a transient IGF-1 spike, and supplied a monitoring schedule. No cited human overdose series established those conclusions or a dose-response boundary.
The defensible conclusion is narrower: capture the exposure, use Poison Control for case-specific triage, and escalate emergency symptoms immediately. This page cannot clear an exposure or replace that assessment.
Medical review of this revision is pending. NLM, FDA, Poison Control, trial investigators, institutions, and authors do not endorse tesamorelin, HealthRX.com, or this page.
Frequently asked questions
What amount of tesamorelin is an overdose?
Does tesamorelin have an antidote?
Are EGRIFTA WR and EGRIFTA SV interchangeable after a dose error?
When is an exposure an emergency?
References
- National Library of Medicine. Tesamorelin Injection: MedlinePlus Drug Information. Last revised July 15, 2025. Quoted passage: “In case of emergency/overdose,” first sentence. https://medlineplus.gov/druginfo/meds/a611035.html
- U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) Prescribing Information. Revised March 2025; Reference ID 5557578. See sections 2, 5, 6, 7, and the absence of section 10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
- Falutz J; Mamputu JC; Potvin D; Moyle G; Soulban G; Loughrey H; Marsolais C; Turner R; Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of clinical endocrinology and metabolism. 2010 Sep;95(9):4291-304. DOI 10.1210/jc.2010-0490. PMID 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/